Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by beebee1on Oct 01, 2019 10:13am

247 Views

Post# 30181621

RE:RE:where is the topline data?

bb,,,,,,,,,,nope the only data that was to be announced was the TLD where we either met or missed the design end points. So secondary was not in the works yesterday as RVX noted.

I dont want secondary endpoints. I just mean the guys delivering the conference call sat the whole weekend staring at the number of MACE events in the placebo and drug group and RRR% and they actively chose to not release it. There was no embargo on TL data. It could have been provided with some more granularity if there was something that would support the share price. Anyway, I guess already know the answer. Just venting.

Bullboard Posts

How one company is disrupting PoC testing